ResMed (RMD:AX) launched its US Food and Drug Administration-cleared home sleep apnea test, NightOwl, across the US, according to a Friday statement by the company.
The fingertip sensor allows individuals to test for obstructive sleep apnea at home, the statement said.
Shares of the company fell nearly 3% in recent Friday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.